Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $416,000.

  • CG Oncology's Depreciation & Amortization (CF) rose 1880.95% to $416,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $617,000, marking a year-over-year increase of 1613.89%. This contributed to the annual value of $32,000 for FY2024, which is 88.24% up from last year.
  • Latest data reveals that CG Oncology reported Depreciation & Amortization (CF) of $416,000 as of Q3 2025, which was up 166.67% from $156,000 recorded in Q2 2025.
  • CG Oncology's 5-year Depreciation & Amortization (CF) high stood at $416,000 for Q3 2025, and its period low was $4,000 during Q1 2023.
  • Over the past 3 years, CG Oncology's median Depreciation & Amortization (CF) value was $6,000 (recorded in 2023), while the average stood at $64,500.
  • Data for CG Oncology's Depreciation & Amortization (CF) shows a peak YoY spiked of 2,128.57% (in 2025) over the last 5 years.
  • CG Oncology's Depreciation & Amortization (CF) (Quarterly) stood at $4,000 in 2023, then surged by 320.00% to $21,000 in 2024, then spiked by 1,880.95% to $416,000 in 2025.
  • Its last three reported values are $416,000 in Q3 2025, $156,000 for Q2 2025, and $24,000 during Q1 2025.